Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/62659
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
EXTENSIVE TRANSMISSION OF SARS-COV-2 BQ.1∗VARIANT IN A POPULATION WITH HIGH LEVELS OF HYBRID IMMUNITY: A PREVALENCE SURVEY
Autor
Ticona, Juan P. Aguilar
Xiao, Meng
Li, Dan
Nery Jr, Nivison
Hitchings, Matt
Belitardo, Emilia M. M. Andrade
Fofana, Mariam O.
Victoriano, Renato
Cruz, Jaqueline S.
Moraes, Laise de
Strobel, Icaro Morais
Silva, Jessica Jesus
Aragão Filho, Ananias Sena do
Ribeiro, Guilherme S.
Reis, Mitermayer G.
Costa, Federico
Khouri, Ricardo
Ko, Albert I.
Cummings, Derek A.T.
Xiao, Meng
Li, Dan
Nery Jr, Nivison
Hitchings, Matt
Belitardo, Emilia M. M. Andrade
Fofana, Mariam O.
Victoriano, Renato
Cruz, Jaqueline S.
Moraes, Laise de
Strobel, Icaro Morais
Silva, Jessica Jesus
Aragão Filho, Ananias Sena do
Ribeiro, Guilherme S.
Reis, Mitermayer G.
Costa, Federico
Khouri, Ricardo
Ko, Albert I.
Cummings, Derek A.T.
Afiliación
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil / Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States / Department of Laboratory Medicine. State Key Laboratory of Complex Severe and Rare Diseases. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Beijing, China.
Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States / Public Health Emergency Center. Chinese Center for Disease Control and Prevention. Beijing, China.
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil / Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Department of Biostatistics. University of Florida. Gainesville, United States / Emerging Pathogens Institute. University of Florida. Gainesville, United States.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina da Bahia. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States / Universidade Federal da Bahia. Faculdade de Medicina da Bahia. Salvador, BA, Brasil.
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil / Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Department of Biology. University of Florida. Gainesville, United States / Emerging Pathogens Institute. University of Florida. Gainesville, United States.
Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States / Department of Laboratory Medicine. State Key Laboratory of Complex Severe and Rare Diseases. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences and Peking Union Medical College. Beijing, China.
Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States / Public Health Emergency Center. Chinese Center for Disease Control and Prevention. Beijing, China.
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil / Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Department of Biostatistics. University of Florida. Gainesville, United States / Emerging Pathogens Institute. University of Florida. Gainesville, United States.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina da Bahia. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States / Universidade Federal da Bahia. Faculdade de Medicina da Bahia. Salvador, BA, Brasil.
Universidade Federal da Bahia. Instituto de Saúde Coletiva. Salvador, BA, Brasil / Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Ministério da Saúde. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Department of Epidemiology of Microbial Diseases. Yale School of Public Health. New Haven, United States.
Department of Biology. University of Florida. Gainesville, United States / Emerging Pathogens Institute. University of Florida. Gainesville, United States.
Resumen en ingles
Objectives: The SARS-CoV-2 BQ.1* variant rapidly spread globally in late 2022, posing a challenge due to its increased immune evasion. Methods: We conducted a prevalence survey in Brazil from November 16 to December 22, 2022, as part of a cohort study. We conducted interviews and collected nasal samples for reverse transcription-polymerase chain reaction (RT-PCR) testing and whole-genome sequencing. Cumulative incidence was estimated using RT-PCR positivity, cycle threshold values, and external data on the dynamics of RT-PCR positivity following infection. Results: Among 535 participants, 54% had documented SARS-CoV-2 exposure before this outbreak and 74% had received COVID-19 vaccination. In this study, 14.8% tested positive for SARS-CoV-2, with BQ.1* identified in 90.7% of cases. Using case data and cycle threshold values, cumulative incidence was estimated at 56% (95% confidence interval, 36-88%). Of the 79 positive participants, 48.1% had a symptomatic illness, with a lower proportion fulfilling the World Health Organization COVID-19 case definition compared to prior Omicron waves. No participants required medical attention. Conclusions: Despite high population-level hybrid immunity, the BQ.1* variant attacked 56% of our population. Lower disease severity was associated with BQ.1* compared to prior Omicron variants. Hybrid immunity may provide protection against future SARS-CoV-2 variants but in this case was not able to prevent widespread transmission.
Compartir